ProCE Banner Activity

How I Manage Bothersome and Distressing Side Effects from PARP Inhibitors and ADT in Patients with Prostate Cancer

Clinical Thought

In this expert commentary, Sarah Traverso, MMS, PA-C, describes how advance practice providers can help optimize quality of life for patients with metastatic castrate-resistant prostate cancer receiving PARP inhibitor–based therapy.

Released: November 30, 2022

Expiration: November 29, 2023

No longer available for credit.



Sarah Traverso

Sarah Traverso, MMS, PA-C

Physician Assistant
Division of Genitourinary Oncology
Northwestern Medicine
Chicago, Illinois

Provided by

ProCE Banner


This activity is supported by


Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC

Additional Information

Program Medium

This program has been made available online.